Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.
Pankti Reid, MD, MPH, rheumatologist, assistant professor of medicine, University of Chicago Medicine, discusses remaining challenges regarding the management of immune-related adverse effects (irAEs).
Although the advent of multidisciplinary toxicity teams has facilitated efficient evaluation and management of multi-organ irAEs, challenges remain, Reid says. Moreover, optimization of diagnostic tools and identification of efficacious therapies beyond steroids, is needed.
Systemic steroids, which are currently the standard of care for managing irAEs, are associated with significant toxicities of their own, explains Reid. Additionally, managing irAEs often calls for high-dose steroids given over a long period of time.
As such, developing steroid-sparing regimens is necessary to reduce the potential impact of treatment for irAEs, concludes Reid.
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
2 Commerce Drive
Cranbury, NJ 08512